These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 26181187)
21. Assessing tumor-related signs and symptoms to support cancer drug approval. Williams G; Pazdur R; Temple R J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497 [TBL] [Abstract][Full Text] [Related]
22. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891 [TBL] [Abstract][Full Text] [Related]
24. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Kluetz PG; Chingos DT; Basch EM; Mitchell SA Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687 [TBL] [Abstract][Full Text] [Related]
25. Drug development in oncology: a regulatory perspective. Augustus S Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790 [TBL] [Abstract][Full Text] [Related]
26. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology. Ning YM; Maher VE Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202 [TBL] [Abstract][Full Text] [Related]
27. FDA not NIH can speed new drugs. Miller HI Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657 [No Abstract] [Full Text] [Related]
28. Examining Manufacturing Readiness for Breakthrough Drug Development. Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693 [No Abstract] [Full Text] [Related]
29. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration. Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233 [TBL] [Abstract][Full Text] [Related]
30. Patient-Focused Drug Development: A New Direction for Collaboration. Perfetto EM; Burke L; Oehrlein EM; Epstein RS Med Care; 2015 Jan; 53(1):9-17. PubMed ID: 25494232 [TBL] [Abstract][Full Text] [Related]
31. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation. Kwok M; Foster T; Steinberg M Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571 [TBL] [Abstract][Full Text] [Related]
32. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations. Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206 [TBL] [Abstract][Full Text] [Related]
33. How drugs are developed and approved by the FDA: current process and future directions. Ciociola AA; Cohen LB; Kulkarni P; Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999 [TBL] [Abstract][Full Text] [Related]
34. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. Psotka MA; von Maltzahn R; Anatchkova M; Agodoa I; Chau D; Malik FI; Patrick DL; Spertus JA; Wiklund I; Teerlink JR JACC Heart Fail; 2016 Oct; 4(10):791-804. PubMed ID: 27395351 [TBL] [Abstract][Full Text] [Related]
35. Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation. Davis C; Abraham J Sociol Health Illn; 2011 Jul; 33(5):731-47. PubMed ID: 21314687 [TBL] [Abstract][Full Text] [Related]
36. Implementing the Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, Differences, and Shared Challenges in the EMA and US-FDA-Recommended Approaches. Cardot JM; Garcia Arieta A; Paixao P; Tasevska I; Davit B AAPS J; 2016 Jul; 18(4):1039-46. PubMed ID: 27116020 [TBL] [Abstract][Full Text] [Related]
37. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products. Rock EP; Scott JA; Kennedy DL; Sridhara R; Pazdur R; Burke LB J Natl Cancer Inst Monogr; 2007; (37):27-30. PubMed ID: 17951228 [TBL] [Abstract][Full Text] [Related]
38. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals. Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737 [TBL] [Abstract][Full Text] [Related]
39. Economics of new oncology drug development. DiMasi JA; Grabowski HG J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942 [TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Patrick DL; Burke LB; Powers JH; Scott JA; Rock EP; Dawisha S; O'Neill R; Kennedy DL Value Health; 2007; 10 Suppl 2():S125-37. PubMed ID: 17995471 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]